查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988257

视网膜色素变性市场：按类型、产品和最终用户划分 - 2026-2032年全球市场预测

Retinitis Pigmentosa Market by Type, Offering, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，视网膜色素变性市场价值将达到 79.6 亿美元，到 2026 年将成长至 84.5 亿美元，到 2032 年将达到 124 亿美元，年复合成长率为 6.53%。

主要市场统计数据
基准年 2025 79.6亿美元
预计年份：2026年 84.5亿美元
预测年份 2032 124亿美元
复合年增长率 (%) 6.53%

视网膜色素变性临床、诊断和治疗趋势的简要概述，为相关人员的策略决策提供框架。

视网膜色素变性是一种复杂的疾病，涉及遗传因素、进行性性视力丧失以及快速发展的临床和技术应对措施。在分子遗传学、视网膜成像和治疗设备进步的推动下，目前的情况正从单纯的临床观察转向精准诊断和标靶干预。相关人员现在需要一份简洁、循证的分析报告，整合诊断路径、治疗方法和医疗服务，以帮助制定研发和商业化策略。

评估 2025 年美国预期关税调整对眼科治疗供应链韧性、筹资策略和全球临床试验物流的影响。

美国预计2025年的关税调整和贸易政策变化将对视网膜色素变性生态系统产生多方面影响，尤其对跨境零件和技术而言。专用影像设备、基因治疗生产中使用的生物活性材料以及植入式医疗设备零件的进口成本上升，可能会影响医院、诊断中心和眼科专科医疗机构的筹资策略。为此，製造商和临床服务提供者正在评估供应链韧性、本地采购和生产本地化等措施，以降低成本风险并确保关键诊断和治疗工具的可靠供应。

将遗传亚型、诊断方法、治疗途径和医疗保健服务环境与策略发展和实施考虑因素联繫起来的详细細項分析。

了解视网膜色素变性的分型对于协调临床开发和商业策略至关重要。区分体染色体显性遗传、体染色体隐性遗传和X连锁视网膜色素变性对于制定基于类型的研究和策略至关重要，因为每种遗传结构都会导致不同的遗传模式、自然病程和潜在的靶向分子机制。这些差异指导介入通讯协定的合格标准，影响临床咨询方法，并决定特定基因疗法的适用性。

从区域比较观点看美洲、欧洲、中东和非洲以及亚太地区的临床引进、监管差异和能力建构挑战。

区域趋势正在影响视网膜色素变性创新诊断和治疗技术的推广，并推动这些技术走向不同的应用路径。在美洲，临床研究基础设施和专科医疗中心的集中分布，使得临床实验参与者能够快速招募，并能儘早应用先进的影像诊断和介入措施。然而，这也需要与保险公司密切合作，并建立以长期疗效为导向的证据。在该地区，从成功的临床试验到常规临床实践的转化，往往取决于能否透过真实世界数据证明其价值，并使其与永续的报销机制相契合。

企业策略行动和伙伴关係模式塑造了在治疗方法研发、生产规模化以及综合诊断和治疗解决方案方面的领导地位。

产业相关人员正从各自为政的技术孤岛转变为整合诊断、治疗和递送平台的协作生态系统。基因治疗公司越来越多地与专业的合约研发生产机构（CDMO）合作，以应对载体生产的挑战和规模化生产的复杂性。专注于视网膜植入的医疗设备公司正在投资材料科学、感测器介面和手术递送系统，同时寻求与临床中心合作，以在真实临床环境中检验疗效。

透过整合诊断准确性、供应链弹性、监管合规性和分阶段商业化，提供加速部署的实用策略指导。

产业领导者应优先考虑制定整合策略，同时兼顾诊断准确性、治疗可持续性和可操作的交付模式。首先，将临床开发与先进的诊断能力结合，可以提高患者筛选的准确性和终点指标的敏感度。投资于标准化的视网膜电图通讯协定、高解析度光学同调断层扫描(OCT) 成像和集中式影像分析，可以提高临床试验和上市后监测的效率。其次，透过区域製造伙伴关係和采购来源多元化，建立具有韧性的供应链，可以降低贸易中断和关税波动带来的风险，从而确保临床项目的可及性和连续性。

我们采用透明的混合方法研究途径，结合专家访谈、文献分析和资料三角验证，为研究结果提供了实用可靠的见解。

本研究方法结合了跨学科证据整合、专家咨询和方法三角验证，以获得可靠且可操作的见解。主要资料来源是对临床医生、临床实验研究员、生产专家和监管顾问进行的结构化访谈，旨在收集关于诊断方法引入、治疗方法研发挑战和物流实施的第一手观点。辅助研究包括查阅同行评审文献、监管指导文件和公开的临床试验註册信息，以便将研究结果置于当代科学和政策框架中进行解读。

将临床和营运需求结合，使诊断进步和治疗创新保持一致，从而在患者和系统层面产生持久的影响。

视网膜色素变性正处于一个转折点，诊断的明确和治疗的创新正在融合，从而实现日益个性化的治疗路径。识别基因亚型、先进的影像学和电生理检测，以及与多种治疗方法的相互作用，都为改变疾病进程和改善患者预后创造了机会。然而，要实现这一潜力，需要协调投资于实证医学证据的产生、生产基础设施的建设，以及与保险公司的合作，以确保治疗方法能够从临床试验阶段过渡到持续的临床应用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 视网膜色素变性市场：依类型划分

  • 体染色体显性遗传性视网膜色素变性
  • 体染色体隐性遗传性视网膜色素变性
  • X连锁视网膜色素变性

第九章 视网膜色素变性市场：依产品/服务分类

  • 诊断
    • 视网膜电图
    • 眼底照片
    • 光学同调断层扫描
  • 治疗
    • 基因治疗
    • 视网膜植入
    • 干细胞疗法

第十章 视网膜色素变性市场：依最终用户划分

  • 诊断中心
  • 医院和诊所
  • 专科眼科诊所

第十一章 视网膜色素变性市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 视网膜色素变性市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 视网膜色素变性市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国视网膜色素变性市场

第十五章：中国视网膜色素变性市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 4D Molecular Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Axovia Therapeutics
  • Beacon Therapeutics Limited
  • BIOGEN INC.
  • Clino Corporation
  • Editas Medicine, Inc.
  • GENSIGHT BIOLOGICS
  • Horama SA
  • jCyte, Inc.
  • Johnson & Johnson Services, Inc.
  • Kiora Pharmaceuticals, Inc.
  • MeiraGTx Holdings PLC
  • Mimetogen Pharmaceuticals
  • Nacuity Pharmaceuticals
  • Nanoscope Therapeutics, Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Oxford Biomedica PLC
  • Precision BioSciences, Inc.
  • ProQR Therapeutics NV
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.
  • Skyline Therapeutics
  • Spark Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • ViGeneron GmbH
Product Code: MRR-7A1CEDCFE674

The Retinitis Pigmentosa Market was valued at USD 7.96 billion in 2025 and is projected to grow to USD 8.45 billion in 2026, with a CAGR of 6.53%, reaching USD 12.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.96 billion
Estimated Year [2026] USD 8.45 billion
Forecast Year [2032] USD 12.40 billion
CAGR (%) 6.53%

Concise orientation to the evolving clinical, diagnostic, and therapeutic landscape of retinitis pigmentosa that frames strategic decision-making for stakeholders

Retinitis pigmentosa presents a complex intersection of genetics, progressive vision loss, and rapidly evolving clinical and technological responses. The landscape has shifted from descriptive clinical observation to precision diagnostics and targeted interventions, driven by advances in molecular genetics, retinal imaging, and interventional devices. Stakeholders now require concise, clinically grounded analysis that synthesizes diagnostic pathways, therapeutic modalities, and care delivery settings to inform development and commercialization strategies.

This executive summary grounds readers in core clinical characteristics and emerging modalities without presuming prior familiarity with specialized subtypes. It emphasizes translational trends from bench to bedside and highlights how diagnostic resolution-ranging from functional assessments to high-resolution structural imaging-now underpins eligibility for novel therapeutics. By connecting diagnostic sophistication with treatment innovations, the introduction sets the stage for deeper analysis of competitive dynamics, regulatory pressures, and operational considerations that follow.

The retinitis pigmentosa landscape is undergoing transformative shifts driven by converging advances in genetics, imaging, and therapeutic engineering. Gene-based approaches have moved from conceptual phases into clinical assessment, reshaping expectations for durable disease modification. Concurrently, improvements in retinal imaging-especially spectral-domain and swept-source optical coherence tomography and fundus-level modalities-have increased the granularity with which clinicians track progression and stratify patients for trials. These diagnostic enhancements, when combined with standardized functional tests such as electroretinography, create more precise eligibility criteria and accelerate adaptive trial designs.

In parallel, device innovation in retinal implantation and prosthetic interfaces has broadened therapeutic options for patients with advanced photoreceptor loss, while stem cell approaches pursue regenerative pathways with distinct safety and manufacturing profiles. Transitional regulatory frameworks and payer conversations now reflect an understanding that long-term real-world outcomes and quality-of-life metrics will shape adoption. Furthermore, digital health integrations and AI-enabled analysis are enhancing triage and monitoring, enabling decentralized care models that can identify candidates earlier and reduce diagnostic latency. Taken together, these shifts are creating a more integrated ecosystem where diagnostics, therapeutics, and care delivery co-evolve toward patient-centered, evidence-driven pathways.

Assessment of how anticipated 2025 United States tariff adjustments influence supply chain resilience, procurement strategies, and global clinical trial logistics for ocular therapeutics

Anticipated tariff changes and trade policy adjustments in the United States for 2025 have multifaceted implications for the retinitis pigmentosa ecosystem, particularly for components and technologies that cross borders. Increased import costs for specialized imaging equipment, bioactive materials used in gene therapy manufacturing, and implantable device components can affect procurement strategies for hospitals, diagnostic centers, and specialty eye care facilities. In response, manufacturers and clinical providers are evaluating supply chain resilience, regional sourcing, and production localization to mitigate cost exposure and maintain predictable access to critical diagnostic and therapeutic tools.

Beyond raw costs, tariffs influence strategic decisions about where to site manufacturing and final assembly for gene vectors, cell therapy products, and implantable devices. They can also affect the cadence and design of multicenter clinical trials when investigational products and ancillary devices move between sites. Stakeholders increasingly incorporate trade policy scenarios into regulatory planning and contracting with subcontractors. As a result, clinicians and administrators are placing more emphasis on early engagement with suppliers and diversified vendor relationships to preserve continuity of care and trial enrollment despite changing trade dynamics.

In-depth segmentation analysis linking genetic subtypes, diagnostic modalities, therapeutic pathways, and care settings to strategic development and adoption considerations

Understanding segmentation is central to aligning clinical development and commercial strategies in retinitis pigmentosa. When studies and strategies are informed by Type, differentiation among autosomal dominant retinitis pigmentosa, autosomal recessive retinitis pigmentosa, and X-linked retinitis pigmentosa is essential because each genetic architecture yields different inheritance patterns, natural history considerations, and targetable molecular mechanisms. These distinctions guide eligibility criteria for interventional protocols, influence counseling approaches in clinical practice, and determine the applicability of specific gene-based modalities.

Similarly, segmentation based on Offering clarifies where investments and operational resources should be allocated. Diagnosis and Treatment represent two complementary pillars of care. Under Diagnosis, electroretinography offers functional assessment of retinal response, fundus photography provides wide-field structural context, and optical coherence tomography supplies high-resolution cross-sectional views; together they form a diagnostic toolkit that supports stratification and monitoring. Under Treatment, gene therapy pursues corrective or augmentative approaches at the molecular level, retinal implantation seeks to restore visual input through engineered prostheses, and stem cell therapy aims to replace or rescue degenerating cells-each pathway presents distinct regulatory, manufacturing, and long-term evidence considerations.

End-User segmentation further informs distribution and adoption strategy across care settings. Diagnostic centers, hospitals and clinics, and specialty eye care centers each play unique roles in patient identification, procedural delivery, and longitudinal follow-up. Diagnostic centers often lead in access to high-throughput imaging and electrophysiology, hospitals and clinics integrate multidisciplinary care and interventional procedures, and specialty eye care centers provide concentrated expertise for advanced therapies and long-term patient management. Aligning product development, education, and reimbursement engagement with these end-user profiles enhances the likelihood of successful adoption and sustained clinical impact.

Comparative regional perspective on clinical adoption, regulatory variation, and capacity-building imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape the diffusion of diagnostic and therapeutic innovations for retinitis pigmentosa and drive differentiated pathways to adoption. In the Americas, clinical research infrastructures and a high concentration of specialty care centers enable rapid trial recruitment and early uptake of advanced imaging and interventional procedures, but they also necessitate robust payer engagement and evidence generation focused on long-term outcomes. Transitioning from trial success to routine care in this region often hinges on demonstrating value through real-world data and aligning with durable reimbursement frameworks.

In Europe, Middle East & Africa, heterogeneous regulatory landscapes and variable healthcare funding models create both challenges and opportunities. High-income jurisdictions within this region often prioritize early access schemes and conditional approvals that can accelerate patient access to innovative therapies, while emerging markets may adopt different pathways emphasizing cost-effectiveness and technology transfer. Building regional partnerships with academic centers and leveraging pan-regional regulatory harmonization efforts can streamline multi-country development strategies.

In the Asia-Pacific region, expanding clinical capabilities, growing investment in biotechnology, and rising adoption of digital health tools are accelerating participation in global research efforts. Local manufacturing initiatives and public-private collaborations can facilitate supply chain diversification and reduce lead times for complex biologics and devices. Consequently, strategies that account for regional regulatory idiosyncrasies, capacity-building partnerships, and phased market entry tend to be more resilient and effective across this diverse set of jurisdictions.

Strategic corporate behaviors and partnership models shaping leadership in therapeutic development, manufacturing scale-up, and integrated diagnostic-therapeutic solutions

Industry participants are evolving from discrete technology silos toward collaborative ecosystems that integrate diagnostics, therapeutics, and delivery platforms. Companies working on gene therapies are increasingly partnering with specialized contract development and manufacturing organizations to address vector production challenges and scale-up complexities. Device-oriented firms focused on retinal implantation are investing in materials science, sensor interfaces, and surgical delivery systems while exploring partnerships with clinical centers to validate outcomes in real-world settings.

Across players pursuing regenerative approaches such as stem cell therapies, there is a growing emphasis on standardized manufacturing protocols, potency assays, and long-term safety monitoring. These priorities drive strategic alliances between clinical research institutions, contract manufacturers, and regulatory consultants to ensure that translational pipelines are robust. Moreover, competitive differentiation frequently emerges from intellectual property around delivery mechanisms, cryopreservation methods, and patient selection algorithms rather than solely from candidate biology. Companies that combine strong clinical evidence generation with scalable manufacturing and clear commercialization pathways position themselves to lead in the evolving landscape.

Action-oriented strategic guidance for integrating diagnostic precision, supply chain resilience, regulatory alignment, and phased commercialization to accelerate adoption

Industry leaders should prioritize integrated strategies that simultaneously address diagnostic precision, therapeutic durability, and practical delivery models. First, aligning clinical development with advanced diagnostic capabilities will improve patient selection and endpoint sensitivity; investments in standardized electroretinography protocols, high-resolution optical coherence tomography imaging, and centralized image analysis can enhance trial efficiency and post-market surveillance. Second, establishing resilient supply chains through regional manufacturing partnerships and diversified sourcing mitigates risks associated with trade disruptions and tariff variability, thereby preserving access and continuity for clinical programs.

Third, engaging early with regulators and payers to define clinically meaningful endpoints and acceptable real-world evidence pathways will accelerate reimbursement discussions and market access. Fourth, adopt a phased commercialization approach that leverages specialty eye care centers for early adoption while building referral networks from diagnostic centers and hospitals to support broader access. Fifth, invest in patient engagement and long-term outcome tracking to demonstrate quality-of-life benefits and to support value-based contracting. By executing against these interlocking recommendations, organizations can translate scientific advances into scalable therapies that reach patients efficiently and sustainably.

Transparent mixed-methods research approach integrating expert interviews, literature synthesis, and data triangulation to underpin practical and reliable insights

The research approach combined multidisciplinary evidence synthesis, expert consultation, and methodological triangulation to develop robust, actionable insights. Primary inputs included structured interviews with clinicians, trial investigators, manufacturing specialists, and regulatory advisors to capture firsthand perspectives on diagnostic adoption, therapeutic development challenges, and deployment logistics. Secondary research comprised a review of peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial registries to contextualize findings within contemporary scientific and policy frameworks.

Data synthesis employed cross-validation techniques to reconcile differing stakeholder perspectives and to identify consistent patterns across evidence streams. Sensitivity checks and methodological audits were applied to ensure that conclusions reflect replicable trends rather than isolated case examples. Limitations of the approach include reliance on available published evidence and stakeholder availability for interviews; where gaps existed, findings were framed conservatively and presented with clear assumptions. Overall, this mixed-methods design supports confident, pragmatic recommendations while transparently acknowledging areas where additional primary data would strengthen specific conclusions.

Synthesis of clinical and operational imperatives that must align to translate diagnostic advances and therapeutic innovation into sustained patient and system-level impact

Retinitis pigmentosa stands at an inflection point where diagnostic clarity and therapeutic innovation converge to enable increasingly personalized care pathways. The interplay between genetic subtype characterization, enhanced imaging and electrophysiology, and multiple therapeutic modalities creates opportunities to alter disease course and improve patient outcomes. However, realizing that potential requires coordinated investment in evidence generation, manufacturing infrastructure, and payer engagement to ensure therapies move from trials into sustained clinical use.

Strategically, stakeholders who prioritize diagnostic integration, supply chain resilience, and early regulatory and payer dialogue will be better positioned to translate scientific advances into durable patient benefit. Continued collaboration across academic centers, clinical sites, industry partners, and policy actors will be essential to standardize outcome measures, optimize patient access, and build the long-term datasets that justify broader adoption. In sum, the field is poised for meaningful progress provided that operational and evidence-generation challenges are addressed in parallel with scientific development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Retinitis Pigmentosa Market, by Type

  • 8.1. Autosomal Dominant Retinitis Pigmentosa
  • 8.2. Autosomal Recessive Retinitis Pigmentosa
  • 8.3. X-linked Retinitis Pigmentosa

9. Retinitis Pigmentosa Market, by Offering

  • 9.1. Diagnosis
    • 9.1.1. Electroretinography
    • 9.1.2. Fundus Photography
    • 9.1.3. Optical Coherence Tomography
  • 9.2. Treatment
    • 9.2.1. Gene Therapy
    • 9.2.2. Retinal Implantation
    • 9.2.3. Stem Cell Therapy

10. Retinitis Pigmentosa Market, by End-User

  • 10.1. Diagnostic Centers
  • 10.2. Hospitals & Clinics
  • 10.3. Specialty Eye Care Centers

11. Retinitis Pigmentosa Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Retinitis Pigmentosa Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Retinitis Pigmentosa Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Retinitis Pigmentosa Market

15. China Retinitis Pigmentosa Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. 4D Molecular Therapeutics, Inc.
  • 16.6. Astellas Pharma Inc.
  • 16.7. Axovia Therapeutics
  • 16.8. Beacon Therapeutics Limited
  • 16.9. BIOGEN INC.
  • 16.10. Clino Corporation
  • 16.11. Editas Medicine, Inc.
  • 16.12. GENSIGHT BIOLOGICS
  • 16.13. Horama SA
  • 16.14. jCyte, Inc.
  • 16.15. Johnson & Johnson Services, Inc.
  • 16.16. Kiora Pharmaceuticals, Inc.
  • 16.17. MeiraGTx Holdings PLC
  • 16.18. Mimetogen Pharmaceuticals
  • 16.19. Nacuity Pharmaceuticals
  • 16.20. Nanoscope Therapeutics, Inc.
  • 16.21. Novartis AG
  • 16.22. Ocugen, Inc.
  • 16.23. Oxford Biomedica PLC
  • 16.24. Precision BioSciences, Inc.
  • 16.25. ProQR Therapeutics N.V.
  • 16.26. Sanofi S.A.
  • 16.27. Santen Pharmaceutical Co., Ltd.
  • 16.28. Skyline Therapeutics
  • 16.29. Spark Therapeutics, Inc.
  • 16.30. Sun Pharmaceutical Industries Ltd.
  • 16.31. Takeda Pharmaceutical Company Limited
  • 16.32. ViGeneron GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY ELECTRORETINOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY FUNDUS PHOTOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY RETINAL IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY EYE CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 108. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 110. GCC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 126. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 127. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 128. G7 RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 132. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 133. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. NATO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA RETINITIS PIGMENTOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)